Loading stock data…
$0.60-0.03 (-4.03%)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Curis, Inc. in the Healthcare sector is trading at $0.60 with a market capitalization of $3M. Wall Street consensus targets $42.67 (3 analysts), implying a +7069.7% move over the next 12 months. The stock is currently near its 52-week low of $0.59, remaining 94.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 3 is oversold, raising the odds of a near-term bounce. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $1.14M↓ | $3.18M↑ | $2.75M |
| Gross Profit | $0 | $0↓ | $1.14M↓ | $3.16M↑ | $2.73M |
| Operating Income | -$9.94M↑ | -$11.52M↓ | -$7.57M↓ | -$6.92M↑ | -$8.25M |
| Net Income | -$8.58M↑ | -$24.20M↓ | $19.36M↑ | -$7.73M↑ | -$8.59M |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...